PE-VC Fund Investments
Pharma co. Rubicon Research attracts Rs.250-Cr from Amansa; GA part exits
Economic Times Rubicon Research
Private equity investor General Atlantic (GA) has sold shares worth INR 250 crore in Thane-based specialty pharmaceutical company Rubicon Research to Amansa Investments through a pre-IPO funding round. As part of the transaction, the GA unit General Atlantic Singapore RR Pte Ltd has sold 51.60 lakh equity shares to Amansa Investments at INR 484.47 per share. It now owns a 54.01% stake in the company.The proposed IPO of the company consists of a fresh issue of shares worth INR 500 crore and an offer-for-sale of shares (OFS) of INR 585 crore. The proceeds from the fresh issue will be used for repayment of debt, acquisitions and general corporate purposes.Founded in 1999, Rubicon Research focuses on creating a value-added product for the pharmaceutical industry as well as developing a portfolio of generic prescription and OTC products.
In Mar 2019, Rubicon Research had attracted about USD 212-M from General Atlantic in return for a majority stake.For FY24, Rubicon Research had reported about INR 854 Cr in Operating Income and about INR 91 Cr in PAT.
Want to receive such news items in your inbox? Click Here to sign up for a trial.
